Blueprint Medicines Corporation (BPMC)
NASDAQ: BPMC · IEX Real-Time Price · USD
112.19
-1.50 (-1.32%)
Jul 26, 2024, 4:30 PM EDT - Market closed
Blueprint Medicines Revenue
Blueprint Medicines had revenue of $96.12M in the quarter ending March 31, 2024, with 51.87% growth. This brings the company's revenue in the last twelve months to $282.21M, up 37.94% year-over-year. In the year 2023, Blueprint Medicines had annual revenue of $249.38M with 22.22% growth.
Revenue (ttm)
$282.21M
Revenue Growth
+37.94%
P/S Ratio
25.22
Revenue / Employee
$430,853
Employees
655
Market Cap
7.02B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 249.38M | 45.34M | 22.22% |
Dec 31, 2022 | 204.04M | 23.96M | 13.30% |
Dec 31, 2021 | 180.08M | -613.66M | -77.31% |
Dec 31, 2020 | 793.74M | 727.22M | 1,093.37% |
Dec 31, 2019 | 66.51M | 21.99M | 49.39% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Jazz Pharmaceuticals | 3.84B |
Penumbra | 1.10B |
HealthEquity | 1.04B |
Halozyme Therapeutics | 862.99M |
Ionis Pharmaceuticals | 776.62M |
Repligen | 607.45M |
Ascendis Pharma | 357.63M |
Revolution Medicines | 4.57M |
BPMC News
- 5 hours ago - Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches - Accesswire
- 1 day ago - Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches - Accesswire
- 2 days ago - Blueprint Medicines Corporation Investors Are Notified By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches - Accesswire
- 7 days ago - Blueprint Medicines Corporation Investors Are Informed By The Schall Law Firm Of Ongoing Investigations Into Possible Securities Law Breaches - Accesswire
- 8 days ago - The Schall Law Firm Is Currently Investigating Potential Violations Of Securities Laws For Investors Of Blueprint Medicines Corporation - Accesswire
- 8 days ago - Blueprint Medicines to Report Second Quarter 2024 Financial Results on Thursday, August 1, 2024 - PRNewsWire
- 9 days ago - The Schall Law Firm Is Presently Probing Possible Breaches Of Securities Laws For Blueprint Medicines Corporation Investors - Accesswire
- 13 days ago - The Schall Law Firm Is At Present Conducting An Inquiry Into Possible Breaches Of Securities Laws For Blueprint Medicines Corporation Investors - Accesswire